Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 4Carcinoma 4Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 114Carboplatin 114Cisplatin 45Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28liposomal doxorubicin 27Bevacizumab 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15sargramostim 12Hyperthermic Intraperitoneal Chemotherapy 12olaparib 11Chemotherapy, Adjuvant 10Surgical Procedures, Operative 9Etoposide 9oregovomab 8mirvetuximab soravtansine 8Nivolumab 8Amifostine 8Therapeutics 7Melphalan 7Erlotinib Hydrochloride 7rucaparib 6aldesleukin 6Oxaliplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ovarian Epithelial × volociximab × Clear all
NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡